Biology and validation of PCSK9 as a novel target to lower LDL-C
Slides (presentation) - Sep. 9, 2014Presentation by prof. John Kastelein, MD, Amsterdam, at PACE symposium 'Innovations in lipid management: Evolving insights and implications from PCSK9 research' on August 30, 2014 at ESC in Barcelona
Download Biology and validation of PCSK9 as a novel target to loer LDL-c Dr Kastelein.pdf
Download Biology and validation of PCSK9 as a novel target to loer LDL-c Dr Kastelein.pdf
To view slides, click on images
The content is aimed for medical professionals. To view this item member registration is needed. Register for free to get unlimited access to our educational resources.